Curevac Agreement

July 18, 2022

CureVac, a German biopharmaceutical company, has been at the forefront of the race for a COVID-19 vaccine. The company recently announced a major agreement with the European Union (EU) to supply up to 405 million doses of its mRNA-based vaccine candidate if it is proven to be safe and effective.

The deal includes an initial purchase of 225 million doses, with an option for the EU to purchase an additional 180 million doses. The agreement also includes the possibility for EU member states to donate doses to lower-income countries.

This agreement is a significant milestone for CureVac, which is currently conducting phase 2b/3 clinical trials for its vaccine candidate. The mRNA technology used in the vaccine has shown promising results in clinical trials for other diseases, such as the flu, and is considered a cutting-edge approach to vaccine development.

The EU has been actively pursuing agreements with multiple vaccine manufacturers to ensure that its citizens have access to a safe and effective COVID-19 vaccine as soon as possible. In addition to the agreement with CureVac, the EU has secured deals with other major vaccine manufacturers, including Pfizer/BioNTech, Moderna, and AstraZeneca.

The EU has also set up the European Vaccines Strategy, which aims to secure enough doses of vaccines for all EU citizens, as well as for neighboring and lower-income countries. The strategy includes funding for research and development, as well as for the purchase and distribution of vaccines.

CureVac’s agreement with the EU is a positive step forward in the fight against COVID-19. However, it is important to note that the vaccine candidate is still in clinical trials and has yet to be proven safe and effective. The vaccine will need to undergo rigorous testing and evaluation before it can be approved for use.

As the world continues to grapple with the pandemic, it is crucial that vaccine development and distribution be approached with transparency and collaboration. The CureVac agreement is an example of how governments, organizations, and private companies can work together to ensure that everyone has access to life-saving vaccines.